Option Care Health, Inc. (NASDAQ:OPCH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Option Care Health, Inc. (NASDAQ:OPCH) has been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $33.00.

Several brokerages recently issued reports on OPCH. UBS Group began coverage on Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price target (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. JPMorgan Chase & Co. boosted their price target on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday. Bank of America upgraded Option Care Health from a “neutral” rating to a “buy” rating and upped their target price for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, Jefferies Financial Group upgraded Option Care Health from a “hold” rating to a “buy” rating and upped their target price for the stock from $26.00 to $35.00 in a research note on Thursday, January 23rd.

Option Care Health Trading Down 0.7 %

Shares of OPCH stock opened at $34.01 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The stock has a market cap of $5.62 billion, a P/E ratio of 28.58, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. The stock has a 50 day simple moving average of $29.83 and a 200 day simple moving average of $28.18. Option Care Health has a 1 year low of $21.39 and a 1 year high of $34.85.

Insiders Place Their Bets

In other news, insider Michael Bavaro sold 30,996 shares of the company’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the transaction, the insider now directly owns 44,974 shares in the company, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Murphy & Mullick Capital Management Corp acquired a new position in shares of Option Care Health during the fourth quarter worth $26,000. UMB Bank n.a. increased its holdings in shares of Option Care Health by 41.7% during the fourth quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock worth $27,000 after buying an additional 346 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Option Care Health by 487.9% during the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company’s stock worth $28,000 after buying an additional 1,005 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company’s stock worth $40,000 after buying an additional 1,099 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its holdings in shares of Option Care Health by 21.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock worth $43,000 after buying an additional 332 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.